Sanofi S.A. generated $44.8 billion ($44.6 billion USD) in FY2024 revenue, with its blockbuster immunology drug Dupixent (dupilumab) contributing $14.3 billion—31.8% of total sales. The French biopharmaceutical giant, formed in 2004 through the merger of Sanofi-Synthelabo and Aventis, employs approximately 76,493 people across more than 100 countries and is executing a strategic transformation to become a pure-play biopharma company through the planned separation of its consumer healthcare unit Opella in Q2 2025.
Sanofi: Key Facts
- Founded: 2004 (modern entity); origins trace to 1973 when Sanofi was founded as an Elf Aquitaine subsidiary
- Headquarters: Paris, France
- CEO: Paul Hudson (appointed September 2019)
- FY2024 Revenue: $44.8 billion ($44.6 billion USD)
- FY2024 Net Income: $6.2 billion ($6.2 billion USD)
- Market Capitalization: Approximately $107.8 billion (June 2026)
- Employees: Approximately 76,493
- Primary Products: Dupixent (immunology), vaccines (Beyfortus, influenza), rare disease therapies (Fabrazyme, Cerezyme)
- Stock Listings: Euronext Paris (SAN), NYSE (SNY)
- CIK: 0001121404
How Does Sanofi Make Money?
Sanofi generates revenue through four business segments. Specialty Care (immunology, rare diseases, oncology, multiple sclerosis) contributed approximately 51.7% of FY2024 revenue at $23.2 billion, driven by Dupixent's $14.3 billion in sales. General Medicines contributed 20.0% at $8.9 billion from established pharmaceuticals including Lantus and Toujeo. Vaccines generated 17.3% at $7.7 billion, led by Beyfortus achieving blockbuster status at $1.9 billion in its first full year. Consumer Healthcare (Opella) represented 10.7% at $4.8 billion from over-the-counter products. The company sells prescription drugs through direct sales forces, hospital contracts, and pharmacy benefit manager negotiations; vaccines through government procurement and seasonal distribution; and consumer products through retail channels.
Who Founded Sanofi and When?
Sanofi was founded on December 20, 1973, as a subsidiary of French state-owned oil company Elf Aquitaine by executives Jean-François Dehecq and René Sautier. The company was established to diversify Elf's holdings into recession-resistant healthcare. The modern Sanofi S.A. entity was formed in 2004 through the $59.4 billion merger of Sanofi-Synthelabo and Aventis, creating one of Europe's largest pharmaceutical companies. The 2011 acquisition of Genzyme Corporation for $20.1 billion pivoted the company toward rare diseases and biotechnology.
What Is Sanofi's Competitive Advantage?
Sanofi's most defensible moat is its rare disease franchise, built over 14 years since the Genzyme acquisition and generating approximately $6.6 billion in 2024 revenue. The combination of complex biologics manufacturing, orphan drug exclusivity, and patient registry relationships creates barriers that generic competitors cannot replicate. Dupixent's first-mover advantage in IL-4/IL-13 inhibition, supported by the 2007 Regeneron partnership, provides differentiation in immunology. Sanofi's vaccine division benefits from century-long institutional knowledge from the Institut Pasteur, while its global commercial infrastructure with direct presence in 100+ countries provides market access that regional competitors cannot match.
How Has Sanofi's Revenue Grown Over Time?
Sanofi's revenue has fluctuated significantly over the past decade. FY2024 revenue of $44.8 billion represented 8.6% growth from FY2023's $41.2 billion, driven by Dupixent's 23.1% increase and new product launches. FY2022 revenue was approximately $46.9 billion, boosted by COVID-19 vaccine and treatment sales that subsequently declined. FY2023 revenue fell to $41.2 billion as these pandemic-related products exited the portfolio. The long-term trend shows growth from approximately $32.7 billion in 2010 to $44.8 billion in 2024, with Dupixent's emergence as the dominant growth driver since 2017. Management guides to high single-digit sales growth in 2025 and has targeted Dupixent peak sales of approximately $24.0 billion by 2030.
Sanofi Business Model Explained
Sanofi operates a research-driven pharmaceutical business model that discovers, develops, manufactures, and markets prescription drugs, vaccines, and consumer healthcare products. The company invests 18.0% of revenue in R&D ($8.1 billion in 2024) to maintain a pipeline of new products, while manufacturing complex biologics at scale for global distribution. Revenue is generated through direct sales to hospitals and physicians, contracts with pharmacy benefit managers and government health programs, and retail distribution for consumer products. The gross margin of 75.7% reflects the high-margin biologics mix, while SG&A at 22.4% of revenue supports global commercial operations. The planned Opella separation in 2025 will transform Sanofi into a pure-play biopharma company, improving operating margins toward 32%.
Sanofi Key Acquisitions
Sanofi's acquisition history reflects its strategic evolution. The 2004 Aventis merger ($59.4 billion) created the modern entity. The 2011 Genzyme acquisition ($20.1 billion) established rare diseases as a core pillar. The 2017 Bioverativ ($11.6 billion) and Ablynx ($4.8 billion) acquisitions strengthened hematology and antibody technology. In 2025, Sanofi executed its most aggressive business development period with the $9.5 billion Blueprint Medicines acquisition (precision oncology), $1.9 billion Dren Bio (bispecific antibodies), $1.5 billion Vicebio (RSV vaccines), and $470 million Vigil Neuroscience (Alzheimer's). These transactions total more than $13 billion and reflect management's urgency to diversify beyond Dupixent.
What Are the Biggest Risks Facing Sanofi?
Sanofi's biggest risk is its 31.8% revenue dependence on Dupixent, which creates existential vulnerability to eventual biosimilar competition. The planned Opella separation removes $4.9 billion in revenue, making the remaining business even more concentrated. US Medicare price negotiation under the Inflation Reduction Act could compress Dupixent's pricing power. The General Medicines segment faces continuous decline from generic competition, with Lantus falling from $6.5 billion peak to $1.7 billion. China's volume-based procurement creates pricing pressure in a key growth market. The Dengvaxia controversy caused lasting reputational damage in Southeast Asia. Finally, R&D productivity must improve to replace Dupixent's eventual revenue contribution, requiring successful development of tolebrutinib, amitelimab, and acquired assets.
Bottom Line
Sanofi is growing, with FY2024 revenue up 8.6% to $44.8 billion and Dupixent driving 23.1% growth to $14.3 billion. The company's transformation to pure-play biopharma status through the Opella separation, combined with $8.1 billion in R&D investment and $13+ billion in 2025 acquisitions, positions it for continued expansion. However, the extreme dependence on Dupixent—31.8% of revenue—creates vulnerability that the pipeline must address before patent expiration in the 2030s. Management's guidance for high single-digit 2025 sales growth and low double-digit business EPS growth assumes successful execution of multiple parallel initiatives including COPD launch acceleration and new product approvals.
